Thyrocare Q2 FY27 Results: Revenue up 25.1% to ₹270.8 Cr, PAT grows 25.7%
Thyrocare reported Q2 FY27 consolidated revenue of ₹270.8 crore (up 25.1% YoY) and PAT before exceptions of ₹60.2 crore (up 25.7% YoY). Standalone revenue grew 26.8% to ₹256.3 crore. The company launched 5 new labs and is proceeding with the ₹141.4 crore divestment of its subsidiary NHL.
The financial results show robust growth, and the strategic divestment of a subsidiary indicates a clear focus on improving core business profitability and efficiency.
The company reported strong year-on-year growth in revenue and PAT, along with operational improvements and strategic initiatives like new lab launches and a divestment that focuses on core business.
Thyrocare Technologies Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a consolidated revenue of ₹270.8 crore, marking a 25.1% year-on-year increase. Profit After Tax (PAT) before exceptional items grew by 25.7% year-on-year.
The standalone revenue for the quarter stood at ₹256.3 crore, a 26.8% increase year-on-year. The company's EBITDA also saw a significant rise, with consolidated EBITDA growing by 24.9% to ₹89.3 crore and standalone EBITDA increasing by 24.6% to ₹86.0 crore.
Key operational highlights include a 14% year-on-year increase in patients to 5.7 million and a 27% year-on-year increase in tests conducted to 61.6 million. The company also reported a 24% year-on-year decrease in complaints per million tests to 2.9, underscoring its commitment to quality.
Thyrocare launched five new labs in Nasik, Madurai, Asansol, Jabalpur, and Jamshedpur during the quarter to strengthen its testing network and improve turnaround times. The company also conducted franchisee and doctor meetings to gather feedback and enhance service delivery.
Furthermore, the company is progressing with the divestment of its subsidiary Nueclear Healthcare (NHL) for ₹141.4 crore. This strategic move aims to sharpen the focus on the core pathology business, which shows a significantly higher Return on Capital Employed (ROCE) compared to NHL.
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.